Nicotine Replacement Therapy — Competitive Intelligence Brief

Nicotine Replacement Therapy (Nicotine Replacement Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine Replacement Therapy (Nicotine Replacement Therapy) — Ottawa Hospital Research Institute. Nicotine replacement therapy delivers nicotine to the body through alternative routes (patches, gum, lozenges, nasal spray, or inhalers) to reduce withdrawal symptoms and cravings during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine Replacement Therapy TARGET	Nicotine Replacement Therapy	Ottawa Hospital Research Institute	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Patch, Nicotine	Patch, Nicotine	Assistance Publique - Hôpitaux de Paris	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Spinosad Topical	Spinosad Topical	Cipher Pharmaceuticals Inc.	marketed	Natural insecticide	Nicotinic acetylcholine receptors; GABA-gated chloride channels
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class